Danielle Hammond
0000-0002-6017-2264
University of Texas MD Anderson Cancer Center
19 papers found
Refreshing results…
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm
Supplemental Table 3 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Supplemental Figure 1 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Supplemental Figure 2 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Supplemental Table 1 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Supplemental Figure 4 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Supplemental Table 4 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Data from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Eosinophilia During Lenalidomide Therapy in Myelodysplastic Syndrome
Supplemental Figure 3 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Supplemental Table 2 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
Reversible Myocardial Edema Secondary to Tagraxofusp-Induced Capillary Leak Syndrome
Clonal haematopoiesis of emerging significance
Can we transfuse wisely in patients undergoing chemotherapy for acute leukemia or autologous stem cell transplantation?
Impact of Bone Marrow Fibrosis in MDS Patients Treated with Azacitidine
Role of Vitamin K Antagonists in the Prevention of Thrombotic Bypass Occlusion After Infrainguinal Venous Bypass
Missing publications? Search for publications with a matching author name.